Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of Targeted "Personalized" Bacteriophage Treatments in Patients With Bacterial Infection of the Urinary Tract

NCT04287478 is registered in ClinicalTrials.gov with Adaptive Phage Therapeutics, Inc. as lead sponsor.

NCT NCT04287478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04287478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of Targeted "Personalized" Bacteriophage Treatments in Patients With Bacterial Infection of the Urinary Tract
Lead sponsor
Adaptive Phage Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 9, 2020
Completion date
February 28, 2023
Enrollment
1 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

urinary tract infection bacterial